BioCentury | Dec 27, 2016
Clinical News

VF001: Ph II started

...evaluate 28 and 280 μg/mL topical VF001 weekly for 12 weeks in about 168 patients. Factor Therapeutics Ltd....
...quality of life (QOL) and safety Status: Phase II started Milestone: Phase II data (4Q17) Julian Zhu VF001 Factor Therapeutics Ltd. Insulin-like...
BioCentury | Jun 9, 2008
Finance

Ebb & Flow

...week after it granted exclusive worldwide rights to its NF-kappa B decoy program to Transcription Factor Therapeutics...
BioCentury | Jun 9, 2008
Company News

Anesiva, Transcription Factor Therapeutics Inc. deal

...next year in inflammatory bowel disease (IBD). Anesiva Inc. (NASDAQ:ANSV), South San Francisco, Calif. Transcription Factor Therapeutics...
BioCentury | Jun 6, 2008
Company News

Transcription Factor receives rights to NF-kappa B program

...Anesiva (NASDAQ:ANSV) granted Transcription Factor Therapeutics (Irvine, Calif.) exclusive worldwide rights to its NF-kappa B decoy program...
BioCentury | Mar 20, 2008
Cover Story

The 'Smoking Gun' in ALS

...levels, but lifespan is extended only a few months. 1 Rilutek, as well as neurotrophic factor therapeutics...
Items per page:
1 - 5 of 5
BioCentury | Dec 27, 2016
Clinical News

VF001: Ph II started

...evaluate 28 and 280 μg/mL topical VF001 weekly for 12 weeks in about 168 patients. Factor Therapeutics Ltd....
...quality of life (QOL) and safety Status: Phase II started Milestone: Phase II data (4Q17) Julian Zhu VF001 Factor Therapeutics Ltd. Insulin-like...
BioCentury | Jun 9, 2008
Finance

Ebb & Flow

...week after it granted exclusive worldwide rights to its NF-kappa B decoy program to Transcription Factor Therapeutics...
BioCentury | Jun 9, 2008
Company News

Anesiva, Transcription Factor Therapeutics Inc. deal

...next year in inflammatory bowel disease (IBD). Anesiva Inc. (NASDAQ:ANSV), South San Francisco, Calif. Transcription Factor Therapeutics...
BioCentury | Jun 6, 2008
Company News

Transcription Factor receives rights to NF-kappa B program

...Anesiva (NASDAQ:ANSV) granted Transcription Factor Therapeutics (Irvine, Calif.) exclusive worldwide rights to its NF-kappa B decoy program...
BioCentury | Mar 20, 2008
Cover Story

The 'Smoking Gun' in ALS

...levels, but lifespan is extended only a few months. 1 Rilutek, as well as neurotrophic factor therapeutics...
Items per page:
1 - 5 of 5